Short- and long-term cause-specific survival of patients with inflammatory breast cancerReport as inadecuate




Short- and long-term cause-specific survival of patients with inflammatory breast cancer - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 5:137

First Online: 22 October 2005Received: 03 May 2005Accepted: 22 October 2005DOI: 10.1186-1471-2407-5-137

Cite this article as: Tai, P., Yu, E., Shiels, R. et al. BMC Cancer 2005 5: 137. doi:10.1186-1471-2407-5-137

Abstract

BackgroundInflammatory breast cancer IBC had been perceived to have a poor prognosis. Oncologists were not enthusiastic in the past to give aggressive treatment. Single institution studies tend to have small patient numbers and limited years of follow-up. Most studies do not report 10-, 15- or 20-year results.

MethodsData was obtained from the population-based database of the Surveillance, Epidemiology, and End Results program of the National Cancer Institute from 1975–1995 using SEER*Stat5.0 software. This period of 21 years was divided into 7 periods of 3 years each. The years were chosen so that there was adequate follow-up information to 2000. ICD-O-2 histology 8530-3 was used to define IBC. The lognormal model was used for statistical analysis.

ResultsA total of 1684 patients were analyzed, of which 84% were white, 11% were African Americans, and 5% belonged to other races. Age distribution was < 30 years in 1%, 30–40 in 11%, 40–50 in 22%, 50–60 in 24%, 60–70 in 21%, and > 70 in 21%. The lognormal model was validated for 1975–77 and for 1978–80, since the 10-, 15- and 20-year cause-specific survival CSS rates, could be calculated using the Kaplan-Meier method with data available in 2000. The data were then used to estimate the 10-, 15- and 20-year CSS rates for the more recent years, and to study the trend of improvement in survival. There were increasing incidences of IBC: 134 patients in the 1975–77 period to 416 patients in the 1993–95 period. The corresponding 20-year CSS increased from 9% to 20% respectively with standard errors of less than 4%.

ConclusionThe improvement of survival during the study period may be due to introduction of more aggressive treatments. However, there seem to be no further increase of long-term CSS, which should encourage oncologists to find even more effective treatments. Because of small numbers of patients, randomized studies will be difficult to conduct. The SEER population-based database will yield the best possible estimate of the trend in improvement of survival for patients with IBC.

List of abbreviationsCProportion cured

CSSCause-specific survival

DFSDisease-free survival

IBCInflammatory breast cancer

MMean

OSOverall survival

SStandard deviation

SEERSurveillance, Epidemiology, and End Results

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-5-137 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Patricia Tai - Edward Yu - Ross Shiels - Juan Pacella - Kurian Jones - Evgeny Sadikov - Shazia Mahmood

Source: https://link.springer.com/







Related documents